Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
Recruiting1 award8 criteria
Toronto, Ontario
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
Monoclonal Antibodies
Combination Immunotherapy for Colorectal Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is testing two special drugs that help the immune system fight a specific type of cancer. The drugs are given to see if they can shrink the cancer. The study focuses on patients who might not respond well to other treatments. The goal is to see if these drugs are safe and effective.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
Recruiting1 awardPhase 1 & 2
Nashville, Tennessee
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Popular Filters
Trials for Colon Cancer Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Trials for Rectal Cancer Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Trials for Metastatic Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Trials for KRAS Positive Patients
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
KRAS G12C Inhibitor
JDQ443 Combinations for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial tests JDQ443, a new drug, combined with other treatments for patients with advanced cancers having the KRAS G12C mutation. The drug aims to stop cancer growth by targeting a specific genetic fault.
Monoclonal Antibodies
PF-07934040 + Other Anti-Cancer Therapies for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Fayetteville, Arkansas
This trial aims to test the safety and effectiveness of a new medication, PF-07934040, either alone or in combination with other anti-cancer treatments. They are looking for participants with advanced solid
Checkpoint Inhibitor
Cancer Vaccine + Nivolumab + Ipilimumab for Pancreatic and Colorectal Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests a special vaccine combined with immune-boosting drugs for patients with advanced pancreatic or colorectal cancer who have had extensive prior treatments. The goal is to train and enhance the immune system to better fight cancer. The vaccine has been used in previous studies to help the immune system recognize cancer cells in pancreatic cancer patients.
KRAS G12C Inhibitor
GDC-6036 for KRAS G12C-Mutated Cancers
Recruiting1 awardPhase 1
La Jolla, California
This trial is testing a new drug called GDC-6036 in patients with advanced or metastatic solid tumors that have a KRAS G12C mutation. The drug works by blocking a faulty part of the cancer cells' genetic code to stop their growth.
Trials for BRAF Positive Patients
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Monoclonal Antibodies
SGN-BB228 for Melanoma
Recruiting1 awardPhase 1
Denver, Colorado
This trial is testing a new drug called SGN-BB228 to see if it can help treat difficult-to-treat cancers like melanoma and other solid tumors. The study will determine the safest amount of the drug to give and check if it works in shrinking or eliminating these tumors. The goal is to find a new treatment option for patients whose cancers are not responding to current therapies.
Kinase Inhibitor
Triple Therapy for Advanced Solid Cancers
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dose of vemurafenib when given with cetuximab and irinotecan hydrochloride to treat patients with solid tumors. Vemurafenib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Monoclonal Antibodies
Encorafenib + Cetuximab + Nivolumab for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a combination of drugs to treat patients with colorectal cancer that has spread and cannot be removed by surgery. The drugs work by blocking enzymes needed for cell growth and by helping the body's immune system attack the cancer.
Phase 3 Trials
Chemotherapy
Nivolumab-relatlimab Combo for Colorectal Cancer
Recruiting2 awardsPhase 3
Rogers, Arkansas
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Chemotherapy
Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Santa Rosa, California
This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.
Monoclonal Antibodies
Amivantamab + FOLFIRI for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Alamitos, California
This trial aims to compare the effectiveness of two different treatment regimens for patients with colorectal cancer that has come back after previous treatment. One group will receive a combination of amivantamab and chemotherapy
Monoclonal Antibodies
Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Alamitos, California
This trial aims to see how long patients with a specific type of colorectal cancer can remain free of the disease when treated with two different drug combinations.
Trials With No Placebo
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.